Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pacira to Begin Selling Exparel

By Drug Discovery Trends Editor | March 29, 2012

PARSIPPANY, N.J. (AP) – Pacira Pharmaceuticals Inc. said it expects to start selling its pain drug Exparel the week of April 9.

Regulators approved Exparel in October as a treatment for pain following surgery. Pacira said it deployed 63 hospital specialists to market the drug in January.

The company said it took a bigger loss in the fourth quarter on increased sales and administrative costs and an impairment charge. Pacira lost $15.3 million, or 72 cents per share. In the fourth quarter of 2010, before Pacira completed its initial public offering, it lost $7 million, or $12.27 cents per share. Revenue rose to $4.2 million from $2.1 million.

Analysts were expecting the company to take a loss of 52 cents per share on $4.1 million in revenue, according to FactSet.

The company said its sales and administrative costs rose to $6.7 million from $2.4 million, and it reported $3 million in costs related to impairment of long-lived assets.

Pacira has two products already on the market: the chemotherapy drug DepoCyte, and the surgical pain drug DepoDur. Both are delivered with the company’s DepoFoam extended-release technology.

Pacira said it lost $43.3 million, or $2.64 per share, in 2011. It lost $27.1 million, or $47.29 per share, in 2010. Revenue grew to $15.7 million from $14.6 million, and the company said it expects $23 million to $25 million in revenue in 2012 excluding sales of Exparel.

Date: March 27, 2012
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE